Literature DB >> 1984802

Stimulation of megakaryocytopoiesis in mice by human recombinant interleukin-6.

R J Hill1, M K Warren, P Stenberg, J Levin, L Corash, R Drummond, G Baker, F Levin, Y Mok.   

Abstract

The in vivo effects of purified human recombinant interleukin-6 (IL-6) on murine megakaryocytopoiesis were examined. IL-6 was administered subcutaneously to Swiss Webster mice, followed by evaluation of bone marrow megakaryocyte ploidy, size and frequency, and median platelet volume 24, 48, and 72 hours after the initiation of IL-6 administration. In addition, bone marrow megakaryocyte morphology was examined using electron microscopy at 72 hours. IL-6 (10,000 U per subcutaneous injection) was administered three times during the first 24 hours, three times during the second 24 hours, and twice during the last 24-hour period. IL-6 bioactivity (10 U/ng) was determined using the IL-6-dependent murine hybridoma cell line B9. Megakaryocyte ploidy distribution, measured by two-color flow cytometry, demonstrated a shift in the modal ploidy class from 16N to 32N and a significant increase in the relative frequency of 64N megakaryocytes 48 and 72 hours (but not 24 hours) after initiation of IL-6 administration (cumulative doses of 60,000 and 80,000 U at 48 and 72 hours, respectively). In addition, ploidy levels were increased in animals that received a cumulative IL-6 dose of only 40,000 U (evaluated after 72 hours). The size of recognizable bone marrow megakaryocytes, determined by the cross-sectional areas of plastic embedded bone marrow megakaryocytes, was increased at the 48-hour (60,000 U IL-6) and 72-hour (80,000 U IL-6) time points. Megakaryocyte frequency, measured by flow cytometry, was unaffected at all time points and doses of IL-6. Median platelet volume, measured by electrical impedance, was not consistently altered by administration of IL-6. Electron microscopic examination of bone marrow megakaryocytes showed an increase in the proportion of megakaryocytes with a wide, peripheral, organelle-deficient zone from 20% +/- 9% (SD) in control animals to 50% +/- 7% (SD) (P less than .02) in animals that received IL-6. No changes were observed in the distribution of the demarcation membranes. IL-6 is a potent stimulator of murine megakaryocytopoiesis, in vivo, and appears to act early in megakaryocyte differentiation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984802

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Proteoglycan 4, a novel immunomodulatory factor, regulates parathyroid hormone actions on hematopoietic cells.

Authors:  Chad M Novince; Amy J Koh; Megan N Michalski; Julie T Marchesan; Jason Wang; Younghun Jung; Janice E Berry; Matthew R Eber; Thomas J Rosol; Russell S Taichman; Laurie K McCauley
Journal:  Am J Pathol       Date:  2011-09-21       Impact factor: 4.307

2.  Cytokine production by a megakaryocytic cell line.

Authors:  B Sandrock; K M Hudson; D E Williams; M A Lieberman
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-04       Impact factor: 2.416

3.  A role for cyclin D3 in the endomitotic cell cycle.

Authors:  J M Zimmet; D Ladd; C W Jackson; P E Stenberg; K Ravid
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

4.  Utilization of imaging flow cytometry to define intermediates of megakaryopoiesis in vivo and in vitro.

Authors:  Kathleen E McGrath
Journal:  J Immunol Methods       Date:  2015-03-17       Impact factor: 2.303

5.  Effects of recombinant human interleukin 6 (rhIL-6) in marmosets (Callithrix jacchus). 1. General toxicity and hematological changes.

Authors:  S Klug; R Neubert; R Stahlmann; R Thiel; B Ryffel; B D Car; D Neubert
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

6.  Circulating CD36 and oxLDL levels are associated with cardiovascular risk factors in young subjects.

Authors:  Luz E Ramos-Arellano; José F Muñoz-Valle; Ulises De la Cruz-Mosso; Aralia B Salgado-Bernabé; Natividad Castro-Alarcón; Isela Parra-Rojas
Journal:  BMC Cardiovasc Disord       Date:  2014-04-28       Impact factor: 2.298

Review 7.  Optimization of protein therapies by polymer-conjugation as an effective DDS.

Authors:  Hiroko Shibata; Shinsaku Nakagawa; Yasuo Tsutsumi
Journal:  Molecules       Date:  2005-01-31       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.